HomeAI · summaries
Storia in 2 fonti
Pharmalittle: We're reading about a Lilly obesity drug trial, statistics for an Alzheimer's drug, and more
Eli Lilly reported that in a late-stage trial, its next-generation obesity drug led to weight loss approaching the effectiveness seen with bariatric surgery
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
- ·
Pharmalittle: We're reading about a Lilly obesity drug trial, statistics for an Alzheimer's drug, and more
Eli Lilly reported that in a late-stage trial, its next-generation obesity drug led to weight loss approaching the effectiveness seen with bariatric surgery
- ·
benzinga.com
Eli Lilly Highlights Positive Foundayo Data At Obesity Conference - Eli Lilly (NYSE:LLY)
Eli Lilly shares gained after late-stage Foundayo data showed double-digit weight loss in adults aged 65 and older across obesity trials.